Tango Therapeutics, Inc.
TNGX
Rank in Stocks
#4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Share Price
$27.18
Last synced: 2026-07-31
Market Cap
$3.38B
Change (1 day)
-1.41%
Change (1 year)
197.05%
Country
US
Trade Tango Therapeutics, Inc. (TNGX)
Category
Healthcare
P/B ratio for Tango Therapeutics, Inc. (TNGX)
P/B ratio as of October 2026 TTM: 3.25
According to Tango Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 3.25. At the end of 2023 the company had a P/B ratio of 3.70.
P/B ratio history for Tango Therapeutics, Inc. from 2019 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.25 | 92.08% |
| 2024 | 1.69 | -54.27% |
| 2023 | 3.70 | 44.94% |
| 2022 | 2.55 | 29.49% |
| 2021 | 1.97 | -79.17% |
| 2020 | 9.46 | -18.62% |
| 2019 | 11.63 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | 92.57% |
US
|
|
| 13.2547 | 308.33% |
US
|
|
| 4.208 | 29.63% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 90.46% |
NL
|
